SOD1 and myeloid sarcoma: These changes are linked to a reduction in antioxidant capacity, as MS patient-derived MSCs demonstrate decreased secretion of the antioxidants superoxide dismutase 1 (SOD1) and glutathione S-transferase p (GSTP).